With the effort of China’s health reform,27 the number of cancer drug approvals has increased sharply since 2017, reaching levels similar to those in the US and the European Union.28 Second, in July 2017, trastuzumab was first listed in China’s reimbursement drug lists for ERBB2-positive breast cancer. The gene discussed is ERBB2; the disease is breast cancer.